These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 22206641

  • 1. N-Acetylcysteine treatment of dystrophic mdx mice results in protein thiol modifications and inhibition of exercise induced myofibre necrosis.
    Terrill JR, Radley-Crabb HG, Grounds MD, Arthur PG.
    Neuromuscul Disord; 2012 May; 22(5):427-34. PubMed ID: 22206641
    [Abstract] [Full Text] [Related]

  • 2. Screening for increased protein thiol oxidation in oxidatively stressed muscle tissue.
    El-Shafey AF, Armstrong AE, Terrill JR, Grounds MD, Arthur PG.
    Free Radic Res; 2011 Sep; 45(9):991-9. PubMed ID: 21696323
    [Abstract] [Full Text] [Related]

  • 3. Treatment with the cysteine precursor l-2-oxothiazolidine-4-carboxylate (OTC) implicates taurine deficiency in severity of dystropathology in mdx mice.
    Terrill JR, Boyatzis A, Grounds MD, Arthur PG.
    Int J Biochem Cell Biol; 2013 Sep; 45(9):2097-108. PubMed ID: 23892094
    [Abstract] [Full Text] [Related]

  • 4. A single 30 min treadmill exercise session is suitable for 'proof-of concept studies' in adult mdx mice: a comparison of the early consequences of two different treadmill protocols.
    Radley-Crabb H, Terrill J, Shavlakadze T, Tonkin J, Arthur P, Grounds M.
    Neuromuscul Disord; 2012 Feb; 22(2):170-82. PubMed ID: 21835619
    [Abstract] [Full Text] [Related]

  • 5. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ, Terrill JR, Assan EB, Grounds MD, Arthur PG.
    J Physiol; 2017 Dec 01; 595(23):7093-7107. PubMed ID: 28887840
    [Abstract] [Full Text] [Related]

  • 6. Oxidative stress and pathology in muscular dystrophies: focus on protein thiol oxidation and dysferlinopathies.
    Terrill JR, Radley-Crabb HG, Iwasaki T, Lemckert FA, Arthur PG, Grounds MD.
    FEBS J; 2013 Sep 01; 280(17):4149-64. PubMed ID: 23332128
    [Abstract] [Full Text] [Related]

  • 7. Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
    Terrill JR, Pinniger GJ, Graves JA, Grounds MD, Arthur PG.
    J Physiol; 2016 Jun 01; 594(11):3095-110. PubMed ID: 26659826
    [Abstract] [Full Text] [Related]

  • 8. Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal mice.
    Piers AT, Lavin T, Radley-Crabb HG, Bakker AJ, Grounds MD, Pinniger GJ.
    Neuromuscul Disord; 2011 Feb 01; 21(2):132-41. PubMed ID: 21055937
    [Abstract] [Full Text] [Related]

  • 9. Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment.
    Radley HG, Davies MJ, Grounds MD.
    Neuromuscul Disord; 2008 Mar 01; 18(3):227-38. PubMed ID: 18207402
    [Abstract] [Full Text] [Related]

  • 10. l-Glutamine administration reduces oxidized glutathione and MAP kinase signaling in dystrophic muscle of mdx mice.
    Mok E, Constantin B, Favreau F, Neveux N, Magaud C, Delwail A, Hankard R.
    Pediatr Res; 2008 Mar 01; 63(3):268-73. PubMed ID: 18287965
    [Abstract] [Full Text] [Related]

  • 11. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1.
    De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, Fraysse B, Mirabella M, Servidei S, Rüegg UT, Conte Camerino D.
    J Pharmacol Exp Ther; 2003 Jan 01; 304(1):453-63. PubMed ID: 12490622
    [Abstract] [Full Text] [Related]

  • 12. Effect of N-acetylcysteine plus deferoxamine on oxidative stress and inflammation in dystrophic muscle cells.
    Moraes LH, Bollineli RC, Mizobuti DS, Silveira Ldos R, Marques MJ, Minatel E.
    Redox Rep; 2015 May 01; 20(3):109-15. PubMed ID: 25361473
    [Abstract] [Full Text] [Related]

  • 13. N-acetylcysteine treatment reduces TNF-α levels and myonecrosis in diaphragm muscle of mdx mice.
    de Senzi Moraes Pinto R, Ferretti R, Moraes LH, Neto HS, Marques MJ, Minatel E.
    Clin Nutr; 2013 Jun 01; 32(3):472-5. PubMed ID: 22727548
    [Abstract] [Full Text] [Related]

  • 14. The location of protein oxidation in dystrophic skeletal muscle from the mdx mouse model of Duchenne muscular dystrophy.
    Iwasaki T, Terrill JR, Kawarai K, Miyata Y, Tagami T, Maeda N, Hasegawa Y, Watanabe T, Grounds MD, Arthur PG.
    Acta Histochem; 2022 Dec 01; 124(8):151959. PubMed ID: 36270048
    [Abstract] [Full Text] [Related]

  • 15. Melatonin improves muscle function of the dystrophic mdx5Cv mouse, a model for Duchenne muscular dystrophy.
    Hibaoui Y, Reutenauer-Patte J, Patthey-Vuadens O, Ruegg UT, Dorchies OM.
    J Pineal Res; 2011 Sep 01; 51(2):163-71. PubMed ID: 21486366
    [Abstract] [Full Text] [Related]

  • 16. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice.
    Hodgetts S, Radley H, Davies M, Grounds MD.
    Neuromuscul Disord; 2006 Oct 01; 16(9-10):591-602. PubMed ID: 16935507
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-β1 blocker.
    Taniguti AP, Pertille A, Matsumura CY, Santo Neto H, Marques MJ.
    Muscle Nerve; 2011 Jan 01; 43(1):82-7. PubMed ID: 21108244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.